Spotlight on the NZ Medical Journal Editorial
A groundbreaking editorial published in the New Zealand Medical Journal on February 13, 2026, has ignited critical discussions within New Zealand's higher education and medical communities. Titled "Is a clinician-researcher career viable in New Zealand?", the piece by Associate Professors Mark J Bolland and Andrew Grey from the University of Auckland's Department of Medicine asserts that pursuing a dual career in clinical practice and investigator-led research is no longer feasible for most clinicians. Drawing from their combined decades of experience as endocrinologists at Greenlane Clinical Centre while leading high-impact studies, the authors highlight systemic barriers that prevent sustained contributions to clinical science.
This viewpoint arrives amid Health Research Council (HRC) announcements prioritizing clinician-researcher development in 2026 Project Grants, yet Bolland and Grey argue these measures fall short of addressing root causes like time scarcity and funding stagnation. Their analysis resonates deeply in New Zealand universities, where medical schools at Auckland and Otago train future clinician-scientists amid shrinking resources.
Understanding the Clinician-Researcher Role
A clinician-researcher, often called a clinician-scientist, bridges patient care and scientific inquiry. These professionals design and lead investigator-initiated studies—typically randomized controlled trials (RCTs), systematic reviews, or cohort analyses—that directly influence evidence-based medicine. In New Zealand, such roles are vital for translating university lab discoveries into practical health improvements, especially in fields like endocrinology, cardiology, and oncology.
Historically, New Zealand boasted a strong reputation, with over 450 publications from the authors alone, including more than 20 RCTs and 100 original articles. However, recent trends show a downward trajectory in high-impact outputs from top journals like The Lancet and JAMA, signaling broader challenges in sustaining this talent pipeline.
Critical Time Constraints in University Positions
The core issue? Time. New consultant clinicians must commit at least 0.5 full-time equivalent (FTE) to clinical duties to build expertise, leaving 0.5 FTE for academia. At institutions like the University of Auckland, this splits into 40% teaching, 40% research, and 20% service—equating to just 8 hours per week for research activities.
- Literature reviews and protocol development: Time-intensive foundational steps.
- Grant writing and ethics approvals: Often spilling into evenings/weekends.
- Ongoing trial management: Data collection, analysis, and reporting.
HRC guidelines mandate minimum FTE commitments (0.1 for principal investigators, 0.03 for named investigators), yet some universities prohibit "time-only" contributions, exacerbating the squeeze. Companion editorial author Professor A Mark Richards from University of Otago Christchurch echoes this, noting 8 hours weekly is inadequate for competitive global research.
Funding Realities: HRC Grants and Low Success Rates
The Health Research Council of New Zealand (HRC), the primary public funder, awarded 413 project grants and 52 programme grants from 2015–2025, split roughly evenly between preclinical and clinical work. Alarmingly, 71% of project principal investigators (PIs) and 84% of programme PIs secured only one grant, with 73–93% led by senior professors/associate professors.
Success rates hover below 10%, demanding prior evidence of success—a Catch-22 for emerging clinician-researchers. Project grants cap at NZ$1.2–1.44 million over 3–5 years, unchanged since 2010 despite 75% salary hikes and 45% consumer price index (CPI) rise. High institutional overheads—115% at Auckland—consume over 40% of budgets, leaving scant room for salaries or expenses.
Scholarships like Clinical Practitioner Fellowships (16 awarded in 10 years) and Sir Charles Hercus Fellowships (64 in 10 years) offer temporary relief but no long-term security. For aspiring researchers, explore academic CV strategies tailored to these competitive applications.
Overheads and Budget Squeeze Impacting Universities
New Zealand's overhead rates dwarf international peers: Auckland and Otago exceed 100%, versus Australia's 20–35%, UK's 20% (university-funded), or US 30–70%. A hypothetical 3-year clinical project budget illustrates the crisis: over NZ$500,000 salaries plus NZ$600,000 overheads total NZ$1.18 million, exhausting funds before trials begin.
This structural inefficiency, coupled with 2025 reforms merging HRC into the New Zealand Research Fund (NZRF) without funding boosts, threatens biomedical capacity at universities. Universities NZ defends rates as comparable, but critics like Richards warn of irrelevance in global science.
Industry Funding: A Variable Lifeline
Some groups leverage industry-sponsored trials for revenue, funding staff and investigator-led work. However, viability ties to commercial priorities—e.g., osteoporosis boomed 1980s–2017 but vanished post-last Phase III trial. Unreliable for 30-year careers, it also diverts time from independent research.
For stable paths, university positions via faculty roles remain key, though limited by the above constraints.
Declining Research Output and Brain Drain Concerns
Scopus data (2000–2024) reveals 358 NZ-affiliated papers in top journals, but numbers trend downward. Funded papers (33% overall) show rising HRC reliance (53–60% post-2018), yet output lags. Universities host 40% of NZ's 15,000 researchers, but clinician-scientist attrition risks talent loss to Australia or UK, where funding per capita is higher.
Compare Singapore's S$37 billion (2026–2030) investment versus NZ's stagnant HRC NZ$120 million annual budget.
Read the full NZMJ editorial for data visualizations.Stakeholder Perspectives from NZ Universities
At University of Auckland, authors Bolland and Grey exemplify past successes but caution juniors. Otago's Richards laments turmoil from SSAG reforms. Medical deans and HRC acknowledge priorities but face fiscal restraint in 2026 Budget. Students in intercalated PhD tracks (e.g., Auckland MBChB) show interest, but post-grad retention falters without protected time.
Balanced views: Some thrive via collaborations, but systemic change needed for scalability.
Case Studies: Successes and Setbacks
Bolland/Grey: Leveraged early group entry for >450 pubs, multiple HRC grants; now unsustainable. Hypothetical junior: PhD complete at 35, but repeated grant failures erode morale after 5–10 years.
- Success factor: Senior mentorship (scarce).
- Setback: One-grant PIs dominate (71%).
Explore clinical research jobs blending roles.
Potential Solutions and Policy Recommendations
Authors imply needs: Increase HRC funding/inflation-adjust grants, cap overheads, expand mid-career salaries, flexible uni splits, international benchmarking. Richards urges compelling cases to policymakers. SSAG/NZRF transition (2026+) offers reform window—advocate via Universities NZ.
Actionable for unis: Protected research FTE, PhD-to-career bridges, interdisciplinary hubs. Individuals: Target HRC 2026 priorities, build networks.
HRC 2026 Projects Guidelines
Implications for Higher Education and Future Outlook
New Zealand universities risk losing clinician-researcher pipelines, weakening medical school outputs and health innovation. Positive: HRC prioritization signals intent; global trends (e.g., clinician-scientist tracks abroad) offer models.
Outlook: Without investment hikes to OECD 3% GDP (NZ at 1.54%), brain drain accelerates. Optimism via targeted reforms.
Career Advice and Next Steps
Aspiring clinician-researchers: Weigh passions against realities; diversify (teaching, consulting). Check higher ed jobs, research positions, career advice, professor ratings. Network at Auckland/Otago events. Despite challenges, contributions matter—start small, advocate change.
